Though vemurafenib or Zelboraf, the brand name under which Roche sold it, was rejected by the National Institute for Health and Clinical Excellence (Nice) earlier, a recent report has revealed that the drug watchdog has approved the drug for use in the NHS.

Finally, ThromboGenics's main drug i. e. eye treatment Jetrea, has gained clearance from U. S. health regulators, which the company believes, has also opened the ways for the Belgian biotechnology company to make some sustainable profits in the industry.

Experts are advising parents to not worry at all regarding the issue of mass recall of common kids' vaccine as they believe that there are no health risks attached to it.

An experimental drug from Eli Lilly Co. been found capable of slowing memory loss in mild Alzheimer's patients considerably, showing a ray of hope to patients of memory-robbing disease.

Published newly in the journal Science Translational Medicine, a report has uncovered that a vaccine, experimental as yet, has proved effective in its Phase 1 clinical trial for women who have already undergone a treatment for cervical lesions.

Recently, the vaccinations for treating typhoid were recalled by drug maker Sanofi Pasteur. The drugs have been recalled by the manufacturer as the content of the effective chemical was less than the required.

The U. S. Food & Drug Administration (FDA) has ordered Teva Pharmaceuticals to pull its generic antidepressant Budeprion XL from the market.

The Kaiser Permanente Vaccine Study Center in Oakland, California - which carried out a new study of Merck's cervical-cancer vaccine Gardasil - has found that the vaccine is not linked to any serious health problems, though it might lead to fainting on the vaccination day, as well as skin infections a fortnight or so later.

On Monday, the drug maker Novartis announced that its drug to treat chronic obstructive pulmonary disease has been approved in the European countries. During clinical trials it has been found that the drug is capable of treating the chronic obstructive pulmonary disease or smoker’s cough within four hours of administering.

Wednesday, it was announced by Biogen Idec Inc. that its experimental drug has passed a late-stage trial and has even achieved its main goal, according to a latest report.

The drug has been developed to treat patients with hemophilia B, which was aimed at controlling bleeding in its late stage experiment. And the firm says that a single injection was able to do the same.